CI

At a glance

ClinicalIndex Comparison Record
Phase 1Recruiting· 10 target
Drug / intervention
YUVA-GT-F801biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03217032
NCT03217032Phase 1RecruitingOn Track
CompareCT.gov

Lentiviral FVIII Gene Therapy for Hemophilia A

Shenzhen Geno-Immune Medical Institute·interventional·Posted Jul 13, 2017·Updated Jun 23, 2026

In Brief

A Phase 1 clinical trial evaluating YUVA-GT-F801 for Hemophilia A. Currently recruiting, targeting 10 participants across 1 site.

Detailed Summary

This study is a Phase I trial using an advanced lentiviral vector to deliver a functional gene for human clotting factor VIII into patients with hemophilia A, to evaluate the safety and efficacy of infusion of lentiviral gene modified autologous stem cells in patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHemophilia A
CountriesChina
Collaborators--

Timeline

Phase 1Recruiting
20182019202020212022202320242025202620272028
First PostedJul 13, 2017
Enrollment StartJun 1, 2025
Primary CompletionMay 31, 2027
Study CompletionJun 1, 2028
TodayJul 1, 2026
Enrollment to primary: 2 yearsPosted 9.0 years agoPrimary completion in 11 months

Arms & Interventions

YUVA-GT-F801experimental

Gene transfer to treat Hemophilia A

Biological: YUVA-GT-F801

Interventions

YUVA-GT-F801biological

Lentiviral factor VIII gene modified autologous hematopoeitic stem cells and mesenchymal stem cells